{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:22:24Z","timestamp":1787239344733,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.581982","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:39:58Z","timestamp":1604363998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma"],"prefix":"10.3389","volume":"7","author":[{"given":"Hong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41568-019-0177-x","article-title":"Clinical actionability of molecular targets in endometrial cancer","volume":"19","author":"Urick","year":"2019","journal-title":"Nat Rev Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/gcc.20219","article-title":"Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC)","volume":"44","author":"van der Klift","year":"2005","journal-title":"Genes Chromosomes Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","article-title":"The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study","volume":"104","author":"Beiner","year":"2007","journal-title":"Gynecol Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2013.03.027","article-title":"The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study","volume":"130","author":"Segev","year":"2013","journal-title":"Gynecol Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.ejso.2006.03.032","article-title":"High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma","volume":"32","author":"Biron-Shental","year":"2006","journal-title":"Eur J Surg Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature."},{"key":"B10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-319-43139-0_3","article-title":"Pathology of endometrial carcinoma","volume":"943","author":"Lax","year":"2017","journal-title":"Adv Exp Med Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00428-015-1728-5","article-title":"Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas","volume":"466","author":"Coenegrachts","year":"2015","journal-title":"Virchows Arch."},{"key":"B12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000475529","article-title":"Tumor heterogeneity in endometrial carcinoma: practical consequences","volume":"85","author":"Gatius","year":"2018","journal-title":"Pathobiology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"v425","DOI":"10.1093\/annonc\/mdz250.052","article-title":"1044P - Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study","volume":"30","author":"O'Malley","year":"2019","journal-title":"Ann Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"mdy487.042","DOI":"10.1093\/annonc\/mdy487.042","article-title":"70O A phase Ia\/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors","volume":"29","author":"Deva","year":"2018","journal-title":"Ann Oncol."},{"key":"B16","volume-title":"BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)","year":"2019"},{"key":"B17","doi-asserted-by":"publisher","first-page":"v367","DOI":"10.1093\/annonc\/mdz249.019","article-title":"First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic urothelial carcinoma (UC) in Asian patients","volume":"30","author":"Ye","year":"2019","journal-title":"Ann Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget."},{"key":"B19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TOPACIO\/Keynote-162 (NCT02657889): A phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014Results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.2019.37.4_suppl.140","article-title":"An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in patients with relapsed gastric cancer","volume":"37","author":"Bang","year":"2019","journal-title":"J Clin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.581982\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:40:01Z","timestamp":1604364001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.581982\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":21,"alternative-id":["10.3389\/fmed.2020.581982"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.581982","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"article-number":"581982"}}